StemRIM Inc. (JP:4599) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
StemRIM Inc., a biotech venture from Osaka University, has detailed the issuance of its 15th Stock Acquisition Rights to temporary employees and an external collaborator, involving 480 units and 48,000 common stock shares. These stock options, aimed at incentivizing and rewarding their non-permanent workforce, have an exercise price set at 38,500 yen per unit. StemRIM is focused on developing ‘Regeneration-Inducing Medicine’ to harness the body’s natural stem cell capabilities for tissue repair and regeneration in various diseases.
For further insights into JP:4599 stock, check out TipRanks’ Stock Analysis page.